<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03284424</url>
  </required_header>
  <id_info>
    <org_study_id>3475-629</org_study_id>
    <secondary_id>2017-000594-37</secondary_id>
    <secondary_id>MK-3475-629</secondary_id>
    <nct_id>NCT03284424</nct_id>
  </id_info>
  <brief_title>Study of Pembrolizumab (MK-3475) in Adults With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) (MK-3475-629/KEYNOTE-629)</brief_title>
  <official_title>A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475)
      in adult participants with recurrent or metastatic cutaneous Squamous Cell Carcinoma (R/M
      cSCC) that is not amenable to surgery and/or radiation and/or systemic therapies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 26, 2017</start_date>
  <completion_date type="Anticipated">March 14, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 7, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>ORR is defined as the percentage of participants who have best response of Complete Response (CR: Disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>For participants who demonstrate a CR or PR, DOR is defined as the time from first documented evidence of CR or PR per RECIST 1.1 as assessed by BICR until disease progression per RECIST 1.1 assessed by BICR or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>DCR is defined as the percentage of participants who have CR or PR or stable disease (SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease [PD: At least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression.]) for at least 12 weeks per RECIST 1.1 as assessed by BICR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>PFS is defined as the time from first day of study treatment to the first documented disease progression per RECIST 1.1 assessed by BICR or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>OS is defined as the time from first day of study treatment to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Up to approximately 27 months</time_frame>
    <description>An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience one or more AEs will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study Treatment Discontinuations Due to AEs</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be presented.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab 200 mg via intravenous infusion on Day 1 of each 3-week cycle for up to approximately 2 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pembrolizumab</intervention_name>
    <description>intravenous infusion</description>
    <arm_group_label>Pembrolizumab</arm_group_label>
    <other_name>MK-3475</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has cSCC that is either metastatic defined as disseminated disease, and/or
             unresectable disease that is not curable by surgery, radiation, or systemic therapy.

          -  Has histologically-confirmed cSCC as the primary site of malignancy (metastatic skin
             involvement from another primary cancer or from an unknown primary cancer is not
             permitted).

          -  Has metastatic disease defined as disseminated disease distant to the initial/primary
             site of diagnosis, and/or must have locally recurrent disease that has been previously
             treated (with either surgery, radiotherapy, or systemic therapy), and is not amenable
             to either curative surgery, radiotherapy, or concurrent chemoradiotherapy treatment.

          -  Has measurable disease based on RECIST 1.1 as assessed by the central imaging vendor.

          -  Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within
             10 days prior to the start of study treatment.

          -  Has adequate organ function.

          -  Has a tissue sample adequate for programmed death-ligand 1 (PDL1) testing as
             determined by central laboratory testing prior to study allocation.

          -  Has a life expectancy &gt;3 months.

          -  Male participants of childbearing potential must agree to use an adequate method of
             contraception during the study treatment period and for at least 120 days after the
             last dose of study treatment and refrain from donating sperm during this period.

          -  Female participants of childbearing potential must agree to use an adequate method of
             contraception during the study treatment period and for at least 120 days after the
             last dose of study treatment.

        Exclusion Criteria:

          -  Has cSCC that is amenable to surgical resection, local control with radiotherapy, or
             local control with a combination of surgery and radiotherapy, or chemoradiotherapy.

          -  Has any other histologic type of skin cancer other than invasive squamous cell
             carcinoma as the primary disease under study, eg, basal cell carcinoma that has not
             been definitively treated with surgery or radiation, Bowen's disease, Merkel cell
             carcinoma (MCC), melanoma.

          -  Has had any prior allogeneic solid organ or bone marrow transplantation.

          -  Has received prior therapy with an anti-programmed death protein-1 (anti-PD-1),
             anti-programmed death-ligand 1 (anti-PD-L1), or anti-PD-L2 agent or with an agent
             directed to another stimulatory or co-inhibitory T cell receptor (eg, cytotoxic
             T-lymphocyte associated protein 4 [CTLA-4], Tumor necrosis factor receptor
             superfamily, member 4 [OX-40], tumor necrosis factor receptor superfamily member 9
             [CD137]).

          -  Has received prior systemic anti-cancer therapy including investigational agents
             within 4 weeks prior to study allocation.

        (Notes: Participants must have recovered from all AEs due to previously administered
        therapies to â‰¤ Grade 1 or baseline. If a participant received major surgery, they must have
        recovered adequately from the toxicity and/or complications from the intervention prior to
        starting study treatment.)

          -  Has received prior radiotherapy within 2 weeks of start of study treatment.

          -  Is currently participating in or has participated in a study of an investigational
             agent or has used an investigational device within 4 weeks prior to the first dose of
             study treatment.

          -  Has known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis.

          -  Has an active autoimmune disease that has required systemic treatment in the past 2
             years (eg, with use of disease-modifying agents, anticoagulants, corticosteroids or
             immunosuppressive drugs).

          -  Has a history of (noninfectious) pneumonitis that required steroids or has current
             pneumonitis.

          -  Has an active infection requiring systemic therapy.

          -  Has a known history of human immunodeficiency virus (HIV) infection.

          -  Has a known history of Hepatitis B or known active Hepatitis C virus infection.

          -  Is pregnant or breastfeeding or expecting to conceive or father children within the
             projected duration of the study, starting with the screening visit through 120 days
             after the last dose of study treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University Medical Center ( Site 0366)</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>650-492-9551</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Joseph Heritage Healthcare ( Site 0350)</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>707-521-3830</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale University ( Site 0365)</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>203-737-7981</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lombardi Comprehensive Cancer Center ( Site 0360)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>202-687-6871</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana University Melvin and Bren Simon Cancer Center ( Site 0353)</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>317-278-4712</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center ( Site 0361)</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>913-945-7552</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital ( Site 0362)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-724-4000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada ( Site 8001)</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>281-863-4697</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack University Med Ctr ( Site 0367)</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>551-996-5900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0364)</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>918-505-3201</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center ( Site 0351)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>215-214-4297</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sanford Cancer Center Oncology Clinic ( Site 0356)</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>605-328-8000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology PA ( Site 8000)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>281-863-4697</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southern Medical Day Care Centre ( Site 0408)</name>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61242851222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women s Hospital ( Site 0407)</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61736467712</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital ( Site 0405)</name>
      <address>
        <city>Brisbane</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61731763219</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Townsville Hospital ( Site 0404)</name>
      <address>
        <city>Douglas</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61744333548</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lismore Base Hospital ( Site 0402)</name>
      <address>
        <city>Lismore</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61266294559</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orange Health Services ( Site 0406)</name>
      <address>
        <city>Orange</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61263693380</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. Leon Richard Oncology Centre ( Site 0100)</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>H9H 4M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>5068624098</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital Cancer Centre ( Site 0101)</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>H9H 4M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>613737770075051</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre ( Site 0102)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>H9H 4M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>41694645013527</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Research Institute ( Site 0105)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>H9H 4M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>4164804662</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital ( Site 0103)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H9H 4M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>5143408272</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>IUCT - Oncopole ( Site 0604)</name>
      <address>
        <city>Toulouse</city>
        <state>Cedex 9</state>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33567778134</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Avicenne ( Site 0609)</name>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33140257366</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Lille - Hopital Claude Huriez ( Site 0605)</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33320444193</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Limoges CHU Dupuytren ( Site 0608)</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33555056432</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital La Timone ( Site 0603)</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33491387991</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Archet 3 ( Site 0607)</name>
      <address>
        <city>Nice cedex 3</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33492036225</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Louis ( Site 0601)</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33142499595</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Lyon Sud Hospices Civils de Lyon ( Site 0600)</name>
      <address>
        <city>Pierre Benite</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33478861679</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Reims - Hopital Robert Debre ( Site 0610)</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33326784585</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy (IGR) ( Site 0602)</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33142114210</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Essen ( Site 0650)</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+492017232431</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus ( Site 0950)</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97248543811</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center ( Site 0952)</name>
      <address>
        <city>Petah Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97239378004</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center ( Site 0953)</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97235302243</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center. ( Site 0951)</name>
      <address>
        <city>Tel-Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97527360734</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Civil de Guadalajara Fray Antonio Alcalde ( Site 0301)</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+523312250183</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital y Clinica OCA SA de CV/Monterrey International ResearchCenter ( Site 0306)</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+528114777005</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Estatal de Cancerologia de Chihuahua ( Site 0308)</name>
      <address>
        <city>Chihuahua</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+526144106742</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grupo Medico Camino SC ( Site 0300)</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+525541670389</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haukeland Universitetssykehus ( Site 0902)</name>
      <address>
        <city>Bergen.</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4755977118</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo Universitetssykehus Radiumhospitalet ( Site 0901)</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4722934714</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial Barcelona ( Site 0754)</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34932275402</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Duran i Reinals ICO de Hospitalet ( Site 0751)</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34932607744</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Vall D Hebron ( Site 0750)</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3493274600435x0</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal ( Site 0753)</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34913368263</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General de Valencia ( Site 0752)</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34963131800437635</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Clatterbridge Cancer Centre NHS Foundation Trust ( Site 0803)</name>
      <address>
        <city>Bebington</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441515565328</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Marsden NHS Foundation Trust ( Site 0800)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+442078082132</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College Hospital NHS Foundation Trust ( Site 0801)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4402034475085</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Cornwall Hospitals NHS Trust ( Site 0804)</name>
      <address>
        <city>Truro</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441872258310</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Mexico</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://keynoteclinicaltrials.com</url>
    <description>Merck Oncology Clinical Trial Information</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2017</study_first_submitted>
  <study_first_submitted_qc>September 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 15, 2017</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PD1</keyword>
  <keyword>PD-1</keyword>
  <keyword>PDL1</keyword>
  <keyword>PD-L1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

